Monograph Details
|
|
Endocrine System
> Diabetes
|
|
AVAPRO |
| Manufacturer |
|
Bristol-Myers Squibb |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Angiotensin II receptor blocker. |
| Generic Name |
|
Irbesartan 75mg, 150mg, 300mg; tabs. |
| Indications |
|
Treatment of diabetic nephropathy in type 2 diabetes with hypertension. |
| Children |
|
<6yrs: not recommended. 6–12yrs: 75mg once daily; may increase to 150mg once daily. 13–16yrs: 150mg once daily; may increase to 300mg once daily if needed to control BP. |
| Adults |
|
300 mg once daily. |
| Contraindications |
|
Pregnancy (Cat.D in 2nd and 3rd trimesters). |
| Precautions |
|
Correct salt/volume depletion before beginning therapy, or reduce initial dose. Renal impairment. Severe CHF. Renal artery stenosis. Elderly. Pregnancy (Cat.C in 1st trimester). Nursing mothers: not recommended. |
| Interactions |
|
Hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes. |
| Adverse Reactions |
|
Diarrhea, dyspepsia, fatigue, orthostatic hypotension, hyperkalemia, rhabdomyolysis (rare). |
| How Supplied |
Tabs 75mg—30, 90
Tabs 150mg, 300mg—30, 90, 500 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
